🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea flag South Korea · Delayed Price · Currency is KRW
453,000
+31,000 (7.35%)
Nov 20, 2026, 1:15 PM KST

Hanmi Pharm. Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,562,6311,547,5311,495,5021,490,8871,331,5471,203,186
Other Revenue
-0-0---0-
1,562,6311,547,5311,495,5021,490,8871,331,5471,203,186
Revenue Growth
6.58%3.48%0.31%11.97%10.67%11.83%
Cost of Revenue
682,224663,124678,465661,638612,994570,433
Gross Profit
880,407884,407817,037829,249718,553632,752
Selling, General & Admin
444,573430,773421,960426,789406,146361,309
Research & Development
195,834195,834178,891181,769154,317146,027
Other Operating Expenses
-500-----
Operating Expenses
673,836660,536604,526604,364564,657507,336
Operating Income
206,570223,870212,511224,885153,896125,416
Interest Expense
-16,986-16,986-24,374-28,508-22,647-16,577
Interest & Investment Income
7,2667,2665,6664,6187,8565,722
Earnings From Equity Investments
-7.45-7.45-9.21,258-8,537-4.02
Currency Exchange Gain (Loss)
1,4341,4349,3181,039-2,64113.07
Other Non Operating Income (Expenses)
-26,649-3,949-29,309-4,571-3,620-9,277
EBT Excluding Unusual Items
171,628211,628173,802198,721124,308105,293
Gain (Loss) on Sale of Investments
4,7624,762-87.922,63047.09-
Gain (Loss) on Sale of Assets
101.2101.227.741,769451.65-1,062
Asset Writedown
-3,013-3,013-2,488-9,153-3,794-535.2
Pretax Income
173,478213,478171,254193,967121,013103,697
Income Tax Expense
17,74226,34230,82328,60119,45422,218
Earnings From Continuing Operations
155,736187,136140,431165,366101,55881,478
Minority Interest in Earnings
-17,581-17,581-19,116-19,135-18,766-14,453
Net Income
138,154169,554121,315146,23182,79267,025
Net Income to Common
138,154169,554121,315146,23182,79267,025
Net Income Growth
18.60%39.76%-17.04%76.63%23.52%460.45%
Shares Outstanding (Basic)
131313131313
Shares Outstanding (Diluted)
131313131313
Shares Change
0.07%0.07%-0.08%-0.09%-0.12%-0.11%
EPS (Basic)
10887.6313371.579566.8311522.126517.335269.87
EPS (Diluted)
10887.4413362.009566.8311522.126517.335269.87
EPS Growth
18.52%39.67%-16.97%76.79%23.67%461.07%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-130,048154,226189,186131,890181,974
Free Cash Flow Per Share
-10248.7712162.1314906.6710382.3714307.73
Dividend Per Share
2000.0002000.000----
Dividend Growth
------
Gross Margin
-57.15%54.63%55.62%53.96%52.59%
Operating Margin
13.22%14.47%14.21%15.08%11.56%10.42%
Profit Margin
8.84%10.96%8.11%9.81%6.22%5.57%
Free Cash Flow Margin
-8.40%10.31%12.69%9.90%15.12%
EBITDA
307,143322,679309,842323,339250,738214,502
EBITDA Margin
-20.85%20.72%21.69%18.83%17.83%
D&A For EBITDA
100,57298,80997,33198,45496,84289,086
EBIT
206,570223,870212,511224,885153,896125,416
EBIT Margin
-14.47%14.21%15.08%11.56%10.42%
Effective Tax Rate
-12.34%18.00%14.74%16.08%21.43%
Advertising Expenses
-73,81778,78976,03472,62762,201